Navigation Links
Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Date:9/3/2007

KENILWORTH and WHITEHOUSE STATION, N.J., Aug. 28 /PRNewswire-FirstCall/ -- Schering-Plough/Merck Pharmaceuticals (SPM) today announced that the New Drug Application filing for loratadine/montelukast has been accepted by the U.S. Food and Drug Administration (FDA) for standard review.

Schering-Plough/Merck Pharmaceuticals is seeking U.S. marketing approval of loratadine/montelukast for treatment of allergic rhinitis symptoms in patients who want relief from nasal congestion. If approved the medicine would be marketed as a prescription treatment by Schering-Plough/Merck Pharmaceuticals, a joint venture between Schering-Plough Corporation (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK).

The medicine is a single tablet that contains the active ingredients of CLARITIN (R) (loratadine) and SINGULAIR (R) (montelukast sodium), both of which are indicated for the relief of symptoms of allergic rhinitis.

About Allergic Rhinitis

Allergic rhinitis affects more than 50 million people in the United States (1,2) and accounts for more than 14 million physician office visits each year.(3) It is one of the most costly chronic illnesses in the United States (4) and is estimated to cause 100 million days of lost work per year.(5)

There are two forms of allergic rhinitis: seasonal and perennial. Seasonal allergic rhinitis occurs only during certain times of the year and is commonly caused by allergies to tree, grass and weed pollen (often referred to as "hay- fever"). Per
'/>"/>

SOURCE Schering-Plough/Merck Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... , ... Cosmetic Town Journal is an online plastic surgery ... successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients and connecting ... help. , It is clear that the Cosmetic Town aesthetic surgery community has ...
(Date:8/31/2015)... ... August 31, 2015 , ... Southern Vacation Rentals – a member of ... fellow South Walton property management company, 360 Blue, in support of the ... of the world. The two companies will collect any unopened food items left in ...
(Date:8/31/2015)... ... 2015 , ... India Network Foundation, a non-profit US-based sponsor ... summarizes all available plans, plan maximums, pre-existing condition coverage limits and deductible in ... Network members make an informed decision regarding the care they want for their ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... management program that is unique to the Lake Orion area. This program is ... County. , WEmovestrong’s weight management program will incorporate group fitness and nutritional ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... President, Marketing and Corporate Communications. In this capacity, Michael will provide strategic leadership ... an industry leader in consumer-focused programs that have contributed to the company’s rapid ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
... Medical Center demonstrates that, for certain patient populations, an ... cost effective treatment. The implantable device, called Rheos, ... drug resistant hypertension. The study which ... Hypertension used data from two large population-based ...
... not so far-fetched, say scientists who now have possible ... -- Researchers have identified a potential target for drug ... cord scar tissue release molecules that prevent severed nerve ... connections that would restore feeling and movement. , In ...
... ... for the life science, engineering and entertainment industries, announced today they have signed an ... devices incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer ...
... following is a statement of Matthew L. Myers, President, ... ) , A landmark report released today ... that elected officials have no excuse for failing to ... smoke-free laws reduce the number of heart attacks and ...
... finds sharp hikes in blood pressure when overweight, air pollution ... appears to hit the obese hardest, causing significant increases in ... been linked to a variety of health problems including asthma, ... obesity has been taken into account, researchers say. , "For ...
... the Slovenian capital, is hosting the EAU 9th Central ... 24 October. Professor Ciril Oblak (Ljubljana, SI) is chairman ... differences between Western European and Central European countries in ... dom Cultural and Congress Centre is this year,s CEM ...
Cached Medicine News:Health News:Cost effectiveness of blood pressure device evaluated 2Health News:Cost effectiveness of blood pressure device evaluated 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Institute of Medicine Report Concludes Smoke-Free Laws Prevent Heart Attacks; It's Time to Make All Workplaces and Public Places Smoke-Free 2Health News:Institute of Medicine Report Concludes Smoke-Free Laws Prevent Heart Attacks; It's Time to Make All Workplaces and Public Places Smoke-Free 3Health News:Smog Tougher on the Obese 2Health News:Smog Tougher on the Obese 3Health News:Ljubljana center of Europe during EAU 9th Central European meeting 2
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: